...
首页> 外文期刊>Journal of Surgical Oncology >Caspase14 expression is associated with triple negative phenotypes and cancer stem cell marker expression in breast cancer patients
【24h】

Caspase14 expression is associated with triple negative phenotypes and cancer stem cell marker expression in breast cancer patients

机译:Caspase14表达与乳腺癌患者的三重阴性表型和癌症干细胞标志物表达有关

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Background and Objectives The Caspase14 (CASP14) was reported that the low expression of CASP14 in ovarian cancer and colon cancer was associated with cancer progression, on the other hand, that the CASP14 expression in breast cancer was higher than that of non‐cancerous tissues. The purpose of this study is to determine the clinical significance of CASP14 in breast cancer. Methods We performed immunohistochemistry for CASP14, ER, PgR, HER2, Ki67, EGFR, CK5/6, CD44, CD24, ALDH1, claudins, and androgen receptor in 222 breast cancer patients including 55 TNBC cases, and evaluated the relationship of CASP14, above‐mentioned markers, and prognosis. Using public microarray database of breast cancer, the prognostic value of CASP14 was calculated. Results High CASP14 expression was significantly associated with TNBC subtype ( P ?=?0.015), nuclear grade ( P ?=?0.006), Ki67, EGFR ( P? ?0.001, P ?=?0.016), ALDH1, CD44 and CD24 ( P? ?0.001, P? ?0.001, P ?=?0.001) in 222 breast cancer cases, and the high expression of claudin1 ( P ?=?0.017), and androgen receptor ( P ?=?0.002) in TNBC cases was related to the high CASP14. According to the public database, survival in the high CASP14 breast cancer patients was shorter than low CASP14 patients. Conclusions High CASP14 expression is a marker of breast cancer aggressiveness in association with proliferation, TNBC phenotype, and cancer stemness.
机译:背景技术Caspase14(Casp14)据报道,卵巢癌和结肠癌中Casp14的低表达与癌症进展相关,另一方面,乳腺癌中的Casp14表达高于非癌组织。本研究的目的是确定Casp14在乳腺癌中的临床意义。方法我们对222例乳腺癌患者中的CasP14,ER,PGR,HER2,KI67,EGFR,CK5 / 6,CD44,CD24,ALDH1,CLADINS和雄激素受体进行了免疫组化。(包括55吨TNBC病例,并评估了上面的CASP14的关系 - 释放标记,预后。使用乳腺癌公共array数据库,计算CASP14的预后值。结果高CASP14表达与TNBC亚型(P?= 0.015),核等级(P?= 0.006),KI67,EGFR(P 1 0.001,P≤X.016),ALDH1,CD44和在222例乳腺癌病例中,CD24(p 1 0.001,p≤0.001,p≤0.001),以及Claudin1的高表达(p?= 0.017)和雄激素受体(p?=?在TNBC病例中0.002)与高CASP14有关。根据公共数据库,高科技患者的高科技癌症患者的存活率比低CASP14患者短。结论高CASP14表达是乳腺癌侵袭性与增殖,TNBC表型和癌症症相关的标志物。

著录项

  • 来源
    《Journal of Surgical Oncology》 |2017年第6期|共10页
  • 作者单位

    Department of Diagnostic PathologyGunma University Graduate School of MedicineMaebashi Japan;

    Department of Diagnostic PathologyGunma University Graduate School of MedicineMaebashi Japan;

    Research Program for Omics‐Based Medical Science Division of Integrated Oncology ResearchGunma;

    Department of Molecular Pharmacology and OncologyGunma University Graduate School of;

    Integrative Center of General SurgeryGunma University HospitalMaebashi Japan;

    Department of Molecular Pharmacology and OncologyGunma University Graduate School of;

    Department of Molecular Pharmacology and OncologyGunma University Graduate School of;

    Department of General Surgical Science Graduate School of MedicineGunma UniversityMaebashi Japan;

    Department of Molecular Pharmacology and OncologyGunma University Graduate School of;

    Department of Oncology Clinical DevelopmentGunma University Graduate School of MedicineMaebashi;

    Department of Oncology Clinical DevelopmentGunma University Graduate School of MedicineMaebashi;

    Big Data Center for Integrative AnalysisGunma University Initiative for Advance Research (GIAR;

    Integrative Center of General SurgeryGunma University HospitalMaebashi Japan;

    Research Program for Omics‐Based Medical Science Division of Integrated Oncology ResearchGunma;

    Department of Diagnostic PathologyGunma University Graduate School of MedicineMaebashi Japan;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 肿瘤学;
  • 关键词

    CASP14; luminal androgen receptor; stem cell marker; therapeutic target; triple negative breast cancer;

    机译:CASP14;腔雄激素受体;干细胞标志物;治疗目标;三重阴性乳腺癌;

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号